-+ 0.00%
-+ 0.00%
-+ 0.00%

Immuneering to present Phase 2a atebimetinib combo survival data in pancreatic cancer at ASCO

PUBT·04/21/2026 20:15:39
Listen to the news
Immuneering to present Phase 2a atebimetinib combo survival data in pancreatic cancer at ASCO
  • Immuneering scheduled new survival results from Phase 2a trial of atebimetinib (IMM-1-104) with modified gemcitabine/nab-paclitaxel in first-line advanced or metastatic pancreatic cancer for presentation at 2026 ASCO Annual Meeting.
  • Data will be presented June 1, 2026, in an oral rapid abstract session.
  • Presentation will cover expanded cohort of 55 first-line patients, up from previously reported 34.
  • Update is positioned to support atebimetinib’s profile on survival-related outcomes, including durable tumor control, preservation of body mass, and tolerability.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuneering Corporation published the original content used to generate this news brief on April 21, 2026, and is solely responsible for the information contained therein.